IGP research “Best Basic Investigation” in Journal of Nuclear Medicine
A research team at IGP has had their latest study selected as Best Basic Investigation and overall Featured Article of the Month in the highly ranked Journal of Nuclear Medicine. The work demonstrates a strong therapeutic potential of a new targeted radiopharmaceutical for cancer treatment.
The figure from the article, selected for the journal cover.
The study validates a radioactively labelled antibody designed to deliver radiation selectively to cancer cells. In several tumour models, the treatment showed high and specific tumour uptake, favourable dosimetry, and strong anti-tumour effects, including complete tumour regression in a large proportion of treated animals. Importantly, the therapy was well tolerated in multiple animal species, with low uptake in healthy tissues, supporting a favourable safety profile.
Based on these results, the radioantibody, which is called [¹⁷⁷Lu]Lu-AKIR001, has now advanced into first-in-human clinical testing for patients with certain tumours.
The researchers have presented their results in Journal of Nuclear Medicine, where it was selected was selected as Best Basic Investigation and overall Featured Article of the Month (February issue). In addition, one of the study figures was featured on the journal cover.
The article, with the title “Preclinical Validation of [¹⁷⁷Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials”, was published together with collaborators at Karolinska Institutet and other Swedish universities.